Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy

Carbohydrate antigen 19‐9 (CA19‐9) is a widely used biomarker in pancreatic cancer. There is no consensus on the interpretation of the change in CA19‐9 serum levels and its role in the clinical management of patients with pancreatic cancer.

[1]  J. Berlin,et al.  Current Treatment Options for Pancreatic Carcinoma , 2011, Current oncology reports.

[2]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[3]  John A. Swets,et al.  Evaluation of diagnostic systems : methods from signal detection theory , 1982 .

[4]  P. Philip,et al.  A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer , 2005, Investigational New Drugs.

[5]  H. Gogas,et al.  Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.

[6]  C. Claussen,et al.  Pancreatic and Ampullary Carcinoma. Ultrasound, Computed Tomography, Magnetic Resonance Imaging and Angiography , 1993, Endoscopy.

[7]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[8]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[9]  P. Philip,et al.  CA19‐9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy , 2010, Asia-Pacific journal of clinical oncology.

[10]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.

[12]  U. Harmenberg,et al.  Serum Levels of CA 19‐9 and CA 50 in Relation to Lewis Blood Cell Status in Patients with Malignant and Benign Pancreatic Disease , 1993, Pancreas.

[13]  CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials , 2005, British Journal of Cancer.

[14]  A. Lipton,et al.  Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer , 2010, Journal of clinical gastroenterology.

[15]  O. Yokosuka,et al.  Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer , 2011, Cancer Chemotherapy and Pharmacology.

[16]  Derrick Wong,et al.  Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy , 2008, Pancreas.

[17]  V. Heinemann,et al.  Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer , 2006, Oncology.

[18]  J. Tepper,et al.  A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma , 2011, Cancer.

[19]  T. Sauerbruch,et al.  Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine , 2003, British Journal of Cancer.

[20]  P. Philip,et al.  Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Xiaobai Li,et al.  A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas , 2011, Cancer Chemotherapy and Pharmacology.

[22]  V. Keim,et al.  Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer , 2000, British Journal of Cancer.

[23]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Chiorean.  A Phase 2 Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003 , 2011 .

[26]  P. Philip,et al.  Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma , 2001, Cancer.

[27]  M. Tempero,et al.  Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer , 2005, British Journal of Cancer.

[28]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[29]  R. Lamerz,et al.  Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin? , 2003, Oncology Research and Treatment.

[30]  E. Saad,et al.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine , 2002, International journal of gastrointestinal cancer.

[31]  R. Frelick.  Cancer and leukemia group B (CALGB). , 1979, Delaware medical journal.

[32]  Xiaobai Li,et al.  VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  W. Scheithauer,et al.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.

[34]  A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma , 1996, Cancer.

[35]  K. Syrigos,et al.  A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer , 2006, British Journal of Cancer.

[36]  M. Herlyn,et al.  Specific antigen in serum of patients with colon carcinoma. , 1981, Science.

[37]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[41]  J. Maurel,et al.  CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone , 2009, British Journal of Cancer.

[42]  J. Berlin,et al.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Shah.  CA 19-9 as a Prognostic Factor in Inoperable Pancreatic Cancer: The Implication for Clinical Trials , 2006 .